BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38766488)

  • 1. Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors.
    Qi G; Zhang X; Gai X; Yan X
    PeerJ; 2024; 12():e17377. PubMed ID: 38766488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
    Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
    Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
    [No Abstract]   [Full Text] [Related]  

  • 3. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression discordances and clinical values of ER, PR, HER-2 and Ki-67 in primary and metastatic breast cancer].
    Yuan Y; Hu SN; Gao J; Yu Q; Hu YQ; Xu XY; Gao ZG; Zhang J; Zhang Z; Teng Y; Zhang LL
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):681-685. PubMed ID: 31550858
    [No Abstract]   [Full Text] [Related]  

  • 6. Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.
    Georgescu R; Boros M; Moncea D; Bauer O; Coros MF; Oprea A; Moldovan C; Podoleanu C; Stolnicu S
    Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):533-538. PubMed ID: 28099174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
    Falck AK; Fernö M; Bendahl PO; Rydén L
    World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
    Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
    Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
    Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
    Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
    Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
    Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical outcome of receptor expression discordance between primary and metastatic breast cancer].
    Mu YX; Zhang P; Ma F; Yuan P; Wang JY; Xu BH; Li Q
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):506-511. PubMed ID: 30060358
    [No Abstract]   [Full Text] [Related]  

  • 12. Factors Associated With Node-Positive Disease in Estrogen Receptor-Positive Breast Cancer Patients.
    Gallagher J; Elleson KM; Englander K; Chintapally N; Sun W; Whiting J; Laronga C; Lee MC
    J Surg Res; 2024 Mar; 295():327-331. PubMed ID: 38061237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.
    Yang YF; Liao YY; Yang M; Peng NF; Xie SR; Xie YF
    Med Oncol; 2014 Oct; 31(10):214. PubMed ID: 25216864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis.
    Kinoe H; Yamanouchi K; Kuba S; Morita M; Sakimura C; Kanetaka K; Takatsuki M; Abe K; Yano H; Matsumoto M; Otsubo R; Hayashida N; Nagayasu T; Eguchi S
    J BUON; 2018 Dec; 23(7):60-66. PubMed ID: 30722113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
    Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
    Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment.
    Liu J; Deng H; Jia W; Zeng Y; Rao N; Li S; Jin L; Wu J; Song E; Su F
    J Cancer Res Clin Oncol; 2012 May; 138(5):837-42. PubMed ID: 22290394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic diversity and heterogeneity of tumors: a real-world study of metastasis re-biopsy in advanced breast cancer.
    Lv H; Niu L; Zhang M; Zeng H; Zhao S; Yan M
    Chin Med J (Engl); 2022 Sep; 135(17):2076-2082. PubMed ID: 35916549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].
    Liu RB; Zhou XH; Wang JN; Liang HZ; Li XX; Wu ZH; Ye JL; Wang SM
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3397-400. PubMed ID: 19159568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.